Anebulo Pharmaceuticals (NASDAQ:ANEB) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Anebulo Pharmaceuticals (NASDAQ:ANEB) released its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Stock Performance

Shares of ANEB stock opened at $1.96 on Friday. The firm has a market cap of $50.83 million, a price-to-earnings ratio of -5.30 and a beta of -1.01. Anebulo Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $3.61. The firm’s 50-day simple moving average is $2.05 and its two-hundred day simple moving average is $2.35.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.